(Q35580146)

9 August 2017

1 reference

title

New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial (English)

1 reference

9 August 2017

Luis M Ruilope

2

0 references

author name string

Cristina Sierra

series ordinal

1

1 reference

9 August 2017

publication date

1 September 2003

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

169-170

1 reference

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Hyperinsulinemia, insulin resistance, and the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Diabetes and cardiovascular events in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperat

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.026

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2003.026

1 reference

9 August 2017

1 reference